You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
|
|---|---|
| Published in |
The Lancet, November 2012
|
| DOI | 10.1016/s0140-6736(12)61134-9 |
| Pubmed ID | |
| Authors |
David Neal Franz, Elena Belousova, Steven Sparagana, E Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael H Kohrman, J Robert Flamini, Joyce Y Wu, Paolo Curatolo, Petrus J de Vries, Vicky H Whittemore, Elizabeth A Thiele, James P Ford, Gaurav Shah, Helene Cauwel, David Lebwohl, Tarek Sahmoud, Sergiusz Jozwiak |
| Abstract |
Tuberous sclerosis complex is a genetic disorder leading to constitutive activation of mammalian target of rapamycin (mTOR) and growth of benign tumours in several organs. In the brain, growth of subependymal giant cell astrocytomas can cause life-threatening symptoms--eg, hydrocephalus, requiring surgery. In an open-label, phase 1/2 study, the mTOR inhibitor everolimus substantially and significantly reduced the volume of subependymal giant cell astrocytomas. We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 10% |
| United Kingdom | 1 | 10% |
| United States | 1 | 10% |
| France | 1 | 10% |
| Switzerland | 1 | 10% |
| Argentina | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 408 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | <1% |
| United States | 3 | <1% |
| Netherlands | 2 | <1% |
| Korea, Republic of | 1 | <1% |
| United Kingdom | 1 | <1% |
| Denmark | 1 | <1% |
| France | 1 | <1% |
| Canada | 1 | <1% |
| Poland | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 394 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 69 | 17% |
| Other | 44 | 11% |
| Student > Bachelor | 40 | 10% |
| Student > Master | 39 | 10% |
| Student > Ph. D. Student | 34 | 8% |
| Other | 107 | 26% |
| Unknown | 75 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 178 | 44% |
| Agricultural and Biological Sciences | 33 | 8% |
| Neuroscience | 29 | 7% |
| Biochemistry, Genetics and Molecular Biology | 23 | 6% |
| Nursing and Health Professions | 15 | 4% |
| Other | 35 | 9% |
| Unknown | 95 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2022.
All research outputs
#1,427,842
of 25,373,627 outputs
Outputs from The Lancet
#10,065
of 42,669 outputs
Outputs of similar age
#8,748
of 192,576 outputs
Outputs of similar age from The Lancet
#92
of 418 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 42,669 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,576 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 418 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.